Abstract
Oxidative stress and neuronal energy depletion are characteristic biochemical hallmarks of Alzheimer’s disease (AD). It is therefore conceivable that pro-energetic and antioxidant drags such as α-lipoic acid might delay the onset or slow down the progression of the disease. In a previous study, 600 mg α-lipoic acid was given daily to nine patients with AD (receiving a standard treatment with choline-esterase inhibitors) in an open-label study over an observation period of 12 months. The treatment led to a stabilization of cognitive functions in the study group, demonstrated by constant scores in two neuropsychological tests (the mini mental state exam, MMSE and the Alzheimer’s disease assessment score cognitive subscale, ADAScog). In this report, we have extended the analysis to 43 patients over an observation period of up to 48 months. In patients with mild dementia (ADAScog < 15), the disease progressed extremely slowly (ADAScog: +1.2 points/year, MMSE:-0.6 points/year), in patients with moderate dementia at approximately twice the rate. However, the progression appears dramatically lower than data reported for untreated patients or patients on choline-esterase inhibitors in the second year of long-term studies. Despite the fact that this study was not double-blinded, placebo-controlled and randomized, our data suggest that treatment with α-lipoic acid might be a successful ‘neuroprotective’ therapy option for AD. However, a state-of-the-art phase II trial is needed urgently.
Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Similar content being viewed by others
References
AD2000 Collaborative Group (2004) Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 363: 2105–2115
Biewenga GP, Haenen GR, Bast A (1997) The pharmacology of the antioxidant lipoic acid. Gen Pharmacol 29: 315–331
Farlow MR, Lilly ML, Group EBS (2005) Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer’s disease for up to 5 years. BMC Geriatrics 5: 3
Ferris SH, Mackell JA, Mohs R, Schneider LS, Galasko D, Whitehouse PJ, Schmitt FA, Sano M, Thomas RG, Ernesto C, Grundman M, Schafer K, Thal LJ (1997) A multicenter evaluation of new treatment efficacy instruments for Alzheimer’s disease clinical trials, overview and general results. Alzheimer Dis Assoc Disord 11: S1–S12
Frölich L, Riederer P (1995) Free radical mechanisms in dementia of Alzheimer type and the potential for antioxidative treatment. Arzneimittelforschung 45: 443–446
Galasko DR, Gould RL, Abramson IS, Salmon DP (2000) Measuring cognitive change in a cohort of patients with Alzheimer’s disease. Stat Med 19: 1421–1432
Götz ME, Kunig G, Riederer P, Youdim MB (1994) Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 63: 37–122
Hager K, Marahrens A, Kenklies M, Riederer P, Münch G (2001) Alphalipoic acid as a new treatment option for Alzheimer type dementia. Arch Gerontol Geriatr 32: 275–282
Han L, Cole M, Bellavance F, McCusker J, Primeau F (2000) Tracking cognitive decline in Alzheimer’s disease using the Mini-Mental State examination: a meta-analysis. Int Psychogeriatr 12: 231–247
Haxby JV, Raffaele K, Gillette J, Schapiro MB, Rapoport SI (1992) Individual trajectories of cognitive decline in patients with dementia of the Alzheimer type. J Clin Exp Neuropsychol 14: 575–592
Holmquist L, Stuchbury G, Berbaum K, Muscat S, Young S, Hager K, Engel J, Munch G (2006) Lipoic acid as a novel treatment for Alzheimer’s disease and related dementias. Pharmacol Ther 113: 154–164
Mohs RC (1996) Comprehensive and neuropsychologic evaluations: the Alzheimer’s disease assessment scale. Int Psychogeriatr 8: 195–203
Münch G, Schinzel R, Loske C, Wong A, Durany N, Li JJ, Vlassara H, Smith MA, Perry G, Riederer P (1998) Alzheimer’s disease-synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm 105: 439–461
Packer L, Witt EH, Tritschler HJ (1995) alpha-Lipoic acid as a biological antioxidant. Free Radic Biol Med 19: 227–250
Perry G, Castellani RJ, Hirai K, Smith MA (1998) Reactive oxygen species mediate cellular damage in Alzheimer disease. J Alzheimers Dis 1: 45–55
Rascovsky K, Salmon DP, et al. (2005) Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology 65: 397–403
Retz W, Gsell W, Münch G, Rösier M, Riederer P (1998) Free radicals in Alzheimer’s disease. J Neural Transm Suppl 54: 221–236
Rösier M, Retz W, Thome J, Riederer P (1998) Free radicals in Alzheimer’s dementia: currently available therapeutic strategies. J Neural Transm Suppl 54: 211–219
Stern R, Mohs R, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E (1994) A longitudinal study of Alzheimer’s disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 151: 390–396
Storey E, Slavin MJ, Kinsella GJ (2002) Patterns of cognitive impairment in Alzheimer’s disease: assessment and differential diagnosis. Front Biosci 7: el55–el84
Van Gool AW, Weinstein HC, Scheltens P, Walstra GJ (2001) Effect of hydroxychloroquine on progression of dementia in early Alzheimer’s disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet 358: 455–460
Winblad B, Engedal K, et al. (2001) A 1-year, randomized, placebocontrolled study of donepezil in patients with mild to moderate AD. Neurology 57: 489–495
Wong A, Dukic-Stefanovic S, Gasic-Milenkovic J, Schinzel R, Wiesinger H, Riederer P, Münch G (2001) Anti-inflammatory antioxidants attenuate the expression of inducible nitric oxide synthase mediated by advanced glycation endproducts in murine microglia. Eur J Neurosci 14: 1961–1967
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer-Verlag
About this paper
Cite this paper
Hager, K., Kenklies, M., McAfoose, J., Engel, J., Münch, G. (2007). α-Lipoic acid as a new treatment option for Alzheimer’s disease — a 48 months follow-up analysis. In: Gerlach, M., Deckert, J., Double, K., Koutsilieri, E. (eds) Neuropsychiatric Disorders An Integrative Approach. Journal of Neural Transmission. Supplementa, vol 72. Springer, Vienna. https://doi.org/10.1007/978-3-211-73574-9_24
Download citation
DOI: https://doi.org/10.1007/978-3-211-73574-9_24
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-73573-2
Online ISBN: 978-3-211-73574-9
eBook Packages: MedicineMedicine (R0)